212 related articles for article (PubMed ID: 35377411)
1. Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.
Miller M; Kludjian G; Mohrien K; Morita K
Am J Health Syst Pharm; 2022 Jul; 79(15):1245-1249. PubMed ID: 35377411
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.
Kriegl L; Hatzl S; Zurl C; Reisinger AC; Schilcher G; Eller P; Gringschl Y; Muhr T; Meinitzer A; Prattes J; Hoenigl M; Krause R
J Antimicrob Chemother; 2022 Aug; 77(9):2500-2505. PubMed ID: 35726095
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole Sequestration During Extracorporeal Membrane Oxygenation for Invasive Lung Aspergillosis: A Case Report.
Mathieu A; Thiboutot Z; Ferreira V; Benoit P; Grandjean Lapierre S; HÉtu PO; Halwagi A
ASAIO J; 2022 Mar; 68(3):e56-e58. PubMed ID: 33788798
[TBL] [Abstract][Full Text] [Related]
5. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazole use and TDM in real-world pediatric practice.
Fernández Ledesma B; Mendoza-Palomar N; Melendo Pérez S; Fernández-Polo A; Renedo Miró B; Pau Parra A; Luque Pardos S; Grau Cerrato S; Vima Bofarull J; Martín-Gómez MT; Pujol Jover M; Benítez-Carbante MI; Díaz de Heredia C; Soler-Palacin P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0082923. PubMed ID: 37962334
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review.
Mertens B; Elkayal O; Dreesen E; Wauters J; Meersseman P; Debaveye Y; Degezelle K; Vermeersch P; Gijsen M; Spriet I
Antibiotics (Basel); 2023 Jun; 12(7):. PubMed ID: 37508181
[TBL] [Abstract][Full Text] [Related]
9. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
[TBL] [Abstract][Full Text] [Related]
10. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
11. Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation.
Zhao Y; Seelhammer TG; Barreto EF; Wilson JW
Pharmacotherapy; 2020 Jan; 40(1):89-95. PubMed ID: 31742741
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.
Höhl R; Bertram R; Kinzig M; Haarmeyer GS; Baumgärtel M; Geise A; Muschner D; Prosch D; Reger M; Naumann HT; Ficker JH; Kubitz J; Steinmann J; Sörgel F
Mycoses; 2022 Jul; 65(7):747-752. PubMed ID: 35535740
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation.
Winiszewski H; Rougny AC; Lagoutte-Renosi J; Millon L; Capellier G; Navellou JC; Piton G; Clairet AL
Crit Care; 2018 Dec; 22(1):355. PubMed ID: 30577863
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN; Carver PL
Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
[TBL] [Abstract][Full Text] [Related]
19. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
20. Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19.
Bertram R; Naumann HT; Bartsch V; Hitzl W; Kinzig M; Haarmeyer GS; Baumgärtel M; Geise A; Muschner D; Nentwich J; John S; Sörgel F; Steinmann J; Höhl R
Mycoses; 2023 Dec; 66(12):1071-1078. PubMed ID: 37700457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
